Pharmaceutical composition of aspirin and a benzothiazepine for inhibiting platelet aggregation
First Claim
1. A pharmaceutical composition for inhibiting platelet aggregation, which comprises acetylsalicylic acid and (-)-cis-2-(4-methylphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate, wherein the weight ratio of acetylsalicylic acid to (-)-cis-2-(4-methylphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate is 0.3-40:
- 1.
0 Assignments
0 Petitions
Accused Products
Abstract
There is disclosed a pharmaceutical composition for inhibiting the platelet aggregation comprising acetylsalicyclic acid or a pharmaceutically acceptable salt thereof and a 1,5-benzothiazepine derivative of the formula: ##STR1## wherein R1 is a lower alkyl group or a lower alkoxy group, R2 is hydrogen atom or a lower alkanoyl group, R3 is a lower alkyl group, R4 is hydrogen atom or a lower alkyl group and R5 is a lower alkyl group or a halogen atom, or a pharmaceutically acceptable salt thereof.
17 Citations
6 Claims
- 1. A pharmaceutical composition for inhibiting platelet aggregation, which comprises acetylsalicylic acid and (-)-cis-2-(4-methylphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate, wherein the weight ratio of acetylsalicylic acid to (-)-cis-2-(4-methylphenyl)-3-acetoxy-5-[2-(dimethylamino)ethyl]-8-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one maleate is 0.3-40:
Specification